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Mutations in the iPLA2-VIA/PLA2G6 gene are responsible for
PARK14-linked Parkinson’s disease (PD) with α-synucleinopathy.
However, it is unclear how iPLA2-VIA mutations lead to α-synuclein
(α-Syn) aggregation and dopaminergic (DA) neurodegeneration.
Here, we report that iPLA2-VIA–deficient Drosophila exhibits de-
fects in neurotransmission during early developmental stages and
progressive cell loss throughout the brain, including degeneration
of the DA neurons. Lipid analysis of brain tissues reveals that the
acyl-chain length of phospholipids is shortened by iPLA2-VIA loss,
which causes endoplasmic reticulum (ER) stress through membrane
lipid disequilibrium. The introduction of wild-type human iPLA2-VIA
or the mitochondria–ER contact site-resident protein C19orf12 in
iPLA2-VIA–deficient flies rescues the phenotypes associated with
altered lipid composition, ER stress, and DA neurodegeneration,
whereas the introduction of a disease-associated missense mutant,
iPLA2-VIA A80T, fails to suppress these phenotypes. The accelera-
tion of α-Syn aggregation by iPLA2-VIA loss is suppressed by the
administration of linoleic acid, correcting the brain lipid composi-
tion. Our findings suggest that membrane remodeling by iPLA2-
VIA is required for the survival of DA neurons and α-Syn stability.
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Parkinson’s disease (PD) is characterized by loss of themidbrain dopaminergic (DA) neurons, and its clinical fea-
tures include motor symptoms and nonmotor symptoms such as
akinesia, rigidity, tremor, cognitive impairment, sleep disorders,
and dysautonomia (1). Pathologically, a neuronal inclusion
named Lewy body (LB), which contains the presynaptic pro-
tein α-synuclein (α-Syn), ubiquitin, and lipids, is mostly observed
in the affected regions, strongly implying that α-Syn aggregation is
the underlying cause of neurodegeneration in PD. α-Syn presents
as a natively unfolded protein and is folded as an extended
α-helical structure upon binding to the acidic phospholipid sur-
face, which suggests that the altered composition of membrane
lipids could be a trigger of α-Syn aggregation (2, 3).
The nervous system is enriched in lipids and contains a more
diverse lipid composition than other tissues to maintain neuronal
functions (4). Within a given lipid class, different lipid species
are produced from a variety of fatty acids (FAs) with different
lengths and saturation levels. Among them, phospholipids have
important roles in synaptic functions, vesicular transport, and or-
ganelle maintenance (5). The phospholipase A2 (PLA2) family
consists of many subgroups of enzymes that hydrolyze the sn-2 ester
bonds of phospholipids, generating free fatty acids (FFAs) and
lysophospholipids (6). One of the PLA2 members, PLA2G6 or
iPLA2-VIA/iPLA2β, has been isolated as the gene responsible for
an autosomal recessive form of PD linked to the PARK14 locus (7).
Postmortem examinations have revealed a marked LB pathology in
PARK14 cases (7, 8). Depending on the mutation, iPLA2-VIA is
also the causative gene of infantile neuroaxonal dystrophy (INAD)
and neurodegeneration with brain iron accumulation (NBIA) (9,
10). Thus, these 3 different neurodegenerative disorders caused by
iPLA2-VIA mutations are collectively called PLA2G6-associated
neurodegeneration (PLAN). However, the physiological sub-
strates of iPLA2-VIA are still unclear, and it remains controversial
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whether PARK14-associated iPLA2-VIA mutations affect PLA2
activity (11, 12).
Phospholipids are synthesized by 2 pathways: the de novo
pathway (or Kennedy pathway), using acyl-CoAs as donors; and
the remodeling pathway (or Lands’ cycle), in which the cycle of
phospholipid deacylation and reacylation modifies the FA com-
position to generate a mature membrane. iPLA2-VIA has been
proposed to be a key enzyme of the remodeling pathway (6, 13).
Other genes responsible for NBIA, which include Pank2,
C19orf12, COASY, and FA2H, are also suggested to be involved
in lipid metabolism (9). However, it remains largely unknown
how changes in lipid metabolism contribute to PD etiology
accompanied by LB formation and NBIA pathogenesis.
In this study, we show that the loss of iPLA2-VIA leads to the
shortening of the acyl chains of phospholipids in Drosophila,
thereby resulting in disruption of ER homeostasis, alterations in
synaptic vesicle (SV) size and neurotransmission, and DA neuro-
degeneration. Moreover, α-Syn loses affinity for phospholipids
with shorter fatty acyl chains, facilitating α-Syn aggregation in
iPLA2-VIA–deficient flies. Importantly, neuronal expression of
NBIA-associated C19orf12 as well as wild-type (WT) human
iPLA2-VIA, but not the pathogenic iPLA2-VIA mutant A80T,
corrects the altered lipid composition caused by iPLA2-VIA loss,
suppressing the neurodegenerative phenotypes of iPLA2-VIA–
deficient flies. Thus, in addition to genetic evidence that iPLA2-VIA
and C19orf12 underlie a common pathogenic pathway, our re-
sults suggest that iPLA2-VIA–mediated phospholipid remod-
eling is a critical element for α-Syn stability and DA neuron
survival.
Results
Loss of iPLA2-VIA Causes Degeneration of DA Neurons. CG6718 is
the only iPLA2-VIA ortholog (diPLA2-VIA) in the Drosophila
genome, showing 51% amino acid similarity to the human
iPLA2-VIA (hiPLA2-VIA) (14). To determine the effects of a
PD-associated iPLA2-VIA mutation on DA neuron functions,
we generated diPLA2-VIA–null flies by CRISPR/Cas9 technol-
ogy (SI Appendix, Fig. S1 A and B) and reintroduced hiPLA2-
VIAWT or A80T in the diPLA2-VIA–null flies (Fig. 1A). Loss of
diPLA2-VIA caused progressive locomotor defects and sleep dis-
turbance (Fig. 1B and SI Appendix, Fig. S1 C–F). diPLA2-VIA−/−
flies exhibited bang sensitivity, a seizure-and-paralysis behavior
evoked by mechanical shocks (Fig. 1C) (15). Neuronal expres-
sion of hiPLA2-VIAWT largely suppressed the motor and para-
lytic phenotypes by the loss of diPLA2-VIA, suggesting that
hiPLA2-VIA is functional in Drosophila and that its activity in
the central nervous system is sufficient to rescue these pheno-
types (Fig. 1 B and C). In contrast, one of the PARK14 mutants,
hiPLA2-VIAA80T, failed to rescue the neuronal phenotypes of
diPLA2-VIA−/− flies (Fig. 1 B and C) (7, 16).
Consistent with the locomotion phenotype and sleep distur-
bance, which are partly derived from DA neuron dysfunction, the
number of DA neurons in the PPL1, PPM1/2, and PPM3 clus-
ters, as well as survivability, decreased in aged diPLA2-VIA−/−
flies (SI Appendix, Fig. S1 G and H) (17–19). The age-dependent
loss of DA neurons in diPLA2-VIA−/− flies was fully suppressed
by the neuronal expression of hiPLA2-VIAWT, whereas the ex-
pression of hiPLA2-VIAA80T was less effective (Fig. 1 D and E).
Similarly, the sleep disturbance found in diPLA2-VIA−/− flies is
partially corrected by the neuronal expression of hiPLA2-VIAWT
but not of hiPLA2-VIAA80T (SI Appendix, Fig. S1I). In contrast,
the neuronal expression of hiPLA2-VIAWT and hiPLA2-VIAA80T
on the diPLA2-VIA−/− background did not fully rescue the re-
duced lifespan of diPLA2-VIA−/− flies, suggesting that iPLA2-VIA
activity is required for both neuronal and nonneuronal tissues
(SI Appendix, Fig. S1H). To estimate whether A80T has the
properties of a gain-of-function mutation, both hiPLA2-VIAWT
and hiPLA2-VIAA80T were expressed on the diPLA2-VIA+/+
background. Both flies behaved similarly to the normal control in
terms of the motor and paralytic phenotypes and sleep behavior,
which suggests that A80T does not have a gain-of-function prop-
erty (Fig. 1 B and C and SI Appendix, Fig. S1I).
iPLA2-VIA Maintains the Phospholipid Composition in the Brain.
iPLA2-VIA has been proposed to be involved in membrane
homeostasis and remodeling through deacylation of phospho-
lipids (6, 13). To determine the consequence of iPLA2-VIA loss
in lipid metabolism, we analyzed the lipid composition in the brain
of 20-d-old flies and found that phospholipid molecular species
containing myristic acid (C14:0) or palmitoleic acid (C16:1), in-
cluding phosphatidylcholine (PC) 14:0_14:0, phosphatidyletha-
nolamine (PE) 14:0_14:0, PE 14:0_16:1, phosphatidylglycerol
(PG) 14:0_16:1, and phosphatidylserine (PS) 14:0_16:1, were sig-
nificantly increased, while those with acyl chains of 18:0_18:0 and
18:0_18:1, but not 18:0_18:2, were decreased (SI Appendix, Fig. S2
A and B). Accordingly, the ratio of acyl chain 18:0_18:X (X = 0, 1,
and 2) to acyl chains 14:0_14:0 and 14:0_16:1 increased from
0.109 ± 0.003 (mean ± SEM) in the diPLA2-VIA+/+ brain to
0.208 ± 0.008 in the diPLA2-VIA−/− brain (P = 0.0202 by Dunnett’s
test; Fig. 2A). In contrast, the amounts of lysophospholipids and
FFAs such as docosahexaenoic acid (DHA), eicosapentaenoic
acid, and arachidonic acid (ARA), and the proportions of PC, PE,
Fig. 1. Loss of iPLA2-VIA leads to DA neurodegeneration. (A) Comple-
mentary expression of hiPLA2-VIA in diPLA2-VIA−/− flies. Expression of
hiPLA2-VIA was determined by Western blot with anti-hiPLA2-VIA. LacZ and
Actin served as a mock transgene and a loading control, respectively. (B and
C) Defects in motor activity and the bang-sensitive seizure phenotype of
diPLA2-VIA−/− flies are fully rescued by hiPLA2-VIA WT but not A80T. The
climbing assay (n = 20 trials in 20 male flies) and the bang test (n = 5 trials in
10 male flies) were performed using 5-d-old flies, and data are represented
as the mean ± SEM (**P < 0.01 and ***P < 0.001 vs. any other groups in C)
by 1-way ANOVA with the Tukey–Kramer test. N.S., not significant. (D and E)
DA neurons decrease in diPLA2-VIA−/− flies, which is alleviated by hiPLA2-VIA
expression. (D) The PPL1, PPM1/2, and PPM3 cluster DA neurons were visu-
alized in 20-d-old adult brain tissues by an anti-TH antibody. (Scale bar,
50 μm.) (E) The number of TH-positive neurons is graphed. Data are repre-
sented as the mean ± SEM (n = 14 to 21 flies; **P < 0.01 and ***P < 0.001 vs.
diPLA2-VIA+/+; #P < 0.05 vs. hiPLA2-VIAWT by 1-way ANOVA with the Tukey–
Kramer test). Transgenes were driven by the pan-neuronal elav-GAL4 driver.









































PG, and PS, were not significantly changed by diPLA2-VIA loss (SI
Appendix, Fig. S2 C and D). The increased proportion of shorter
acyl chains in diPLA2-VIA−/− brains was also observed at a youn-
ger age, specifically 3 d old (0.089 ± 0.013 vs. 0.057 ± 0.004 in
diPLA2-VIA+/+; P = 0.04 by 2-tailed Student’s t test), and acyl-
chain shortening appeared to be accelerated by aging (SI Appen-
dix, Fig. S2E). Expression of hiPLA2-VIAWT restored the propor-
tion of acyl-chain composition to a normal level (0.115 ± 0.011;
P = 0.97 vs. diPLA2-VIA+/+ by Dunnett’s test), whereas hiPLA2-
VIAA80T had a diminished rescue effect (0.162 ± 0.008; P =
0.565 vs. diPLA2-VIA−/− by Dunnett’s test; Fig. 2A).
Membrane fluidity at a given temperature depends on the lipid
class and acyl-chain composition. Decreases in the acyl-chain
length lower the gel-to-liquid-crystalline phase transition temper-
ature (20). Supporting the finding indicating a decrease in acyl-
chain length, diPLA2-VIA−/− flies exhibited sensitivity to a high
temperature, which was fully rescued by hiPLA2-VIAWT but not
hiPLA2-VIAA80T (Fig. 2B). These data suggest that hiPLA2-VIA
at least partly substituted for diPLA2-VIA in terms of lipid ho-
meostasis and that the A80T mutant exhibited reduced function.
Dietary Manipulation of Acyl-Chain Composition Improves
Neurodegeneration by iPLA2-VIA Loss. A dairy-containing diet in-
fluences lipid metabolism (21–23). The addition of FFAs to diet
modulates the acyl-chain composition of phospholipids in fly
brain tissues (24). To determine whether the alteration of phos-
pholipids in the brain is a primary cause of neuronal phenotypes in
diPLA2-VIA−/− flies, different FFAs, including linoleic acid (LA;
18:2), stearic acid (SA; 18:0), and myristic acid (MA; 14:0), were
administered during a period from the hatching to adult stages. In
parallel, flies were treated with α-tocopherol to prevent lipid
peroxidation because elevated lipid peroxidation was observed in
aged diPLA2-VIA−/− flies, as previously reported (14) (SI Appen-
dix, Fig. S2F). Motor defects observed in adult diPLA2-VIA−/−
flies were fully improved only by the LA-containing diet, whereas
a partial improvement was observed by the SA-containing diet
(Fig. 2C). DA neuron loss and the bang-sensitive seizure pheno-
type in adult diPLA2-VIA−/− flies were also rescued by a diet
containing LA but not by a diet containing MA or α-tocopherol
(Fig. 2 D and E). Consistent with the improvement of neuronal
phenotypes, measurement of brain lipid composition revealed that
the LA-containing diet decreased the proportion of phospholipids
with shorter acyl chains in diPLA2-VIA−/− flies (0.047 ± 0.0007;
P = 0.0004 vs. diPLA2-VIA−/− by Dunnett’s test; Fig. 2A). How-
ever, LA supplementation was unable to fully rescue the reduced
lifespan of diPLA2-VIA−/− flies, which once again suggested the
nonneuronal roles of iPLA2-VIA (SI Appendix, Fig. S1H).
Mitochondrial degeneration has been reported in iPLA2-VIA–
deficient Drosophila and mice (14, 25). We examined whether
membrane lipid disequilibrium caused by iPLA2-VIA loss also
affects mitochondrial activity. However, brain ATP content was
not changed, and mitochondrial morphology in both DA neu-
rons and indirect flight muscles, which is readily compromised by
mutations of mitochondria-associated PD genes such as PINK1
and CHCHD2, was also normal (SI Appendix, Fig. S2 G–I) (26,
27). In addition, LA supplementation failed to rescue the motor
defects and DA neuron loss in CHCHD2- or PINK1-deficient
flies (SI Appendix, Fig. S2 J and K). Together, these data suggest
Fig. 2. hiPLA2-VIA introduction and linoleic acid supplementation reverse
the altered lipid composition and neuronal phenotypes. (A) Higher rate
of shorter acyl chains in diPLA2-VIA−/− and diPLA2-VIA−/− flies expressing
hiPLA2-VIA A80T. The phospholipid composition of the diPLA2-VIA−/− brain
is corrected by dC19orf12 expression or an LA-rich diet. The compositions
of shorter acyl chains (14:0_14:0 and 14:0_16:1) and longer acyl chains
(18:0_18:0, 18:0_18:1, and 18:0_18:2) in phospholipids and the composition
of the phospholipid head groups from 20-d-old adult fly brain tissues are
shown as a bar graph (mean of 3 to 4 independent samples). (B) diPLA2-VIA−/−
flies exhibit sensitivity to high temperature. Twenty-day-old adult flies were
incubated at 37 °C, and the percentage of survivors was calculated at the
indicated time points (mean ± SEM, 3 trials with 10 flies; *P = 0.011, **P <
0.01, and ***P < 0.001 at each time point by 1-way ANOVA with the Tukey–
Kramer test). (C) An LA-rich diet improves motor ability in diPLA2-VIA−/−
flies. The climbing assay was performed by 3-d-old adult flies raised on
normal instant fly food or an instant fly food containing FAs with different
lengths of acyl chains or α-tocopherol (mean ± SEM, n = 10 to 15 flies,
20 trials; ***P < 0.001 by Dunnett’s test; #P < 0.001 vs. diPLA2-VIA−/− [none]
by 1-way ANOVA with the Tukey–Kramer test). (D) An LA-rich diet rescues
DA neuron loss caused by lack of diPLA2-VIA. The number of DA neurons in
each cluster in 20-d-old adult flies (mean ± SEM, n = 11 to 23; *P < 0.05,
**P < 0.01, and ***P < 0.001 by Dunnett’s test; †P < 0.005 and #P < 0.001 vs.
diPLA2-VIA−/− by 1-way ANOVA with the Tukey–Kramer test). (E) The bang-
sensitive seizure-paralysis phenotype of 5-d-old diPLA2-VIA−/− flies is rescued
by LA supplementation. Data are represented as the mean ± SEM (n = 10
male flies, 4 trials; *P < 0.05 by Dunnett’s test).



















































that the alteration of brain lipid composition contributes to
PLAN-linked neurodegeneration and that mitochondrial degen-
eration is not a primary cause of PLAN-linked neurodegeneration.
MPAN-Associated C19orf12 Rescues Neuronal Phenotypes Caused by
iPLA2-VIA Loss.Mutations in the C19orf12 gene are associated with
mitochondrial membrane protein-associated neurodegeneration
(MPAN), an autosomal-recessive disorder that accounts for 5 to
30% of NBIA cases (9). Similar to PD patients, both PLAN and
MPAN patients show a common LB pathology (7, 8, 28). In ad-
dition to the pathological similarity, C19orf12 has been suggested
to be involved in lipid metabolism (9). One of the neuronal phe-
notypes of diPLA2-VIA−/− flies is bang sensitivity, which has also
been reported in C19orf12-knockdown flies (29, 30). Neuronal
overexpression of the C19orf12 homolog CG3740 (dC19orf12)
rescued the heat sensitivity, motor disability, and bang sensitivity
of iPLA2-VIA−/− flies (Fig. 3 A–C and SI Appendix, Fig. S3A).
dC19orf12 overexpression also suppressed DA neuron loss of
diPLA2-VIA−/− flies and partially improved their sleep disturbance
(Fig. 3D and SI Appendix, Fig. S1I). Brain vacuolar formation
caused by diPLA2-VIA loss, which has also been reported pre-
viously (14), was suppressed by dC19orf12 as well as hiPLA2-VIAWT
(Fig. 3 E and F). Consistent with the rescuing effects on
neurodegeneration-associated phenotypes, the increased pro-
portion of shorter acyl chains in phospholipids was corrected to a
normal level by dC19orf12 expression (0.099 ± 0.029; P = 0.589 vs.
diPLA2-VIA+/+ by Dunnett’s test; Fig. 2A). These observations
suggest that iPLA2-VIA and C19orf12 act, at least in part, in the
same pathway for lipid metabolism.
iPLA2-VIA appears to show dynamic localization to the mi-
tochondria and the ER and has some roles in the membranes of
these organelles (14, 25, 30–32). The salivary gland of the
diPLA2-VIA−/− mutant was poorly developed, and the ER areas
of the gland were extended, suggesting that its ER functions were
greatly compromised (Fig. 3G and SI Appendix, Fig. S3B). Al-
tered lipid composition of the ER membrane activates the
ER stress transducer IRE1, which up-regulates the ER stress-
associated transcriptional activator XBP1 through processing
of the XBP1 mRNA precursor (33). Suppression of acyl-chain
shortening in phospholipids by LA treatment mitigated the
morphological defect of the ER and suppressed XBP1 activa-
tion by diPLA2-VIA loss, which indicates that membrane lipid
Fig. 3. Neurodegeneration of diPLA2-VIA−/− flies is rescued by MPAN-associated C19orf12. (A) Neuronal expression of the MPAN-associated gene dC19orf12
improves sensitivity to high temperature. The assay was performed as described in Fig. 2B (mean ± SEM, 3 trials with 10 flies at 20 d old; **P < 0.001 and
***P < 0.0001 by 1-way ANOVA with the Tukey–Kramer test). (B and C) Neuronal expression of dC19orf12 rescues motor disability and bang-sensitive seizures
in diPLA2-VIA−/− flies. The climbing (mean ± SEM, n = 10 to 15 flies, 20 trials) and bang sensitivity (mean ± SEM, n = 30 to 40 flies) assays were performed with
3-d-old adult flies (***P < 0.0001 by 1-way ANOVA with the Tukey–Kramer test). (D) dC19orf12 rescues DA neuron loss caused by lack of diPLA2-VIA. The
number of DA neurons in the indicated clusters is graphed (mean ± SEM, n = 12 to 22 flies at 20 d old; ***P < 0.0001 by 1-way ANOVA with the Tukey–Kramer
test). (E and F) Expression of hiPLA2-VIA WT and dC19orf12 suppresses the vacuolation of the diPLA2-VIA−/− fly brain. (E) Light-microscopic examination of
brain tissue sections from 20-d-old flies with the indicated genotypes. (F) The percentage of total vacuole areas accounting for the optic lobe regions is
graphed (mean ± SEM, n = 3 flies; *P < 0.05 and **P < 0.01 by 1-way ANOVA with the Tukey–Kramer test). (G) Poor development of salivary glands (arrows)
caused by lack of diPLA2-VIA. The salivary glands at the third-instar larval stage were visualized by ER-mAG1. (Scale bar, 1 mm.) (H and I) ER stress in the
salivary glands of the diPLA2-VIA−/− larvae is improved by LA (1 μL/mL) treatment or by the expression of hiPLA2-VIA or dC19orf12. XBP1-GFP and DAPI images
in the salivary glands of third-instar larvae with the indicated genotypes. (Scale bars, 50 μm.) Graphs represent XBP1-GFP signal intensities with the indicated
genotypes (n = 142 to 526 cells in 3 to 12 larvae; ***P < 0.001 by 1-way ANOVA with the Tukey–Kramer test). (J) Neuronal ER stress caused by iPLA2-VIA loss is
relieved by the expression of hiPLA2-VIA or dC19orf12. Images show XBP1-GFP and Elav from an anterior view in the brains of 20-d-old flies. (Scale bar,
50 μm.) Arrowheads indicate XBP1- and Elav-positive signals. Elav was used as a neuron-specific nuclear marker. AL, antennal lobe. Graph represents the
number of XBP1-GFP–positive neurons per brain (n = 9 to 13 flies; **P < 0.005 and ***P < 0.001 by 1-way ANOVA with the Tukey–Kramer test). (K) DA neuron
loss caused by lack of diPLA2-VIA is improved by WT BiP (BiPWT) in diPLA2-VIA−/− flies at 20 d old. The number of DA neurons in the indicated clusters is
graphed (mean ± SEM, n = 7 to 15 flies; *P < 0.01, **P < 0.001, and ***P < 0.0001 by 1-way ANOVA with the Tukey–Kramer test). (L) The bang-sensitive
seizure phenotype is rescued by ChiMERA but not EGFP in diPLA2-VIA−/− flies at 20 d old. Data are represented as the mean ± SEM (n = 17 EGFP and n = 33
ChiMERA flies; ***P < 0.001 by 2-tailed Student’s t test).









































disequilibrium caused by iPLA2-VIA loss evokes ER stress (Fig. 3H
and SI Appendix, Fig. S3B). The ER morphological defect and
XBP1 activation were also mitigated by hiPLA2-VIAWT or
hC19orf12 expression (Fig. 3I and SI Appendix, Fig. S3B). Ad-
ditionally, sporadic XBP1 activation in neurons was observed in
the aged diPLA2-VIA−/− fly brain and suppressed by hiPLA2-VIAWT
or hC19orf12 expression (Fig. 3J). IER1 oligomerization and acti-
vation are negatively regulated by the ER chaperone BiP (34). The
neuronal expression of Drosophila BiP (or Hsc70-3) improved DA
neuron loss due to the lack of diPLA2-VIA (Fig. 3K). BiP
overexpression also ameliorated the bang-sensitivity phenotype
and motor defects through diPLA2-VIA loss (SI Appendix, Fig. S3
C and D). Again, these results suggest that altered lipid compo-
sition caused by iPLA2-VIA loss induces ER stress, presumably
leading to widespread neurodegeneration in addition to DA
neuron degeneration.
We next examined the mechanism by which C19orf12 rescues
ER stress. hC19orf12 has been found at the mitochondria-
associated ER membrane (MAM), among other locations, and
we confirmed that hC19orf12WT is localized at the MAM as well
as the ER and mitochondria in cultured human cells (SI Appendix,
Figs. S3 E, F, and H) (35). In contrast, the MPAN-associated
hC19orf12G69R mutant completely lost its localization to the ER
and mitochondria (SI Appendix, Fig. S3H). hiPLA2-VIAWT and
hiPLA2-VIAA80T were largely localized in the cytoplasm of cul-
tured human cells, as small dot-like structures and hiPLA2-VIAWT
but not hiPLA2-VIAA80T appeared to show partial colocalization
with the ER (SI Appendix, Fig. S3I). Although we did not detect a
physical interaction or colocalization between hiPLA2-VIA and
hC19orf12 (SI Appendix, Fig. S3 G and J), overexpression of
hC19orf12WT increased the number of MAMs, while hC19orf12G69R
failed to do so (SI Appendix, Fig. S3K). To confirm whether
enhanced MAM integrity by C19orf12 rescues ER defects of
diPLA2-VIA−/− flies, we employed the protein ChiMERA, which
consists of the mitochondrial Tom70 fused to the ER protein
Ubc6 and GFP and up-regulates MAM (36). The enhancement
of MAM integrity by ChiMERA also rescued the bang-sensitive
seizure phenotype of diPLA2-VIA−/− flies, suggesting that en-
hanced MAM integrity alleviates the defects in neuronal activity
by correcting membrane lipid disequilibrium (Fig. 3L). How-
ever, ChiMERA expression failed to rescue DA neuron loss in
diPLA2-VIA−/− flies, which suggests that there exists a dynamic
regulatory mechanism of C19orf12 in terms of MAM formation
in response to neuronal activity or that C19orf12 has additional
functions in maintaining the survival of DA neurons (SI Ap-
pendix, Fig. S3L).
Alteration of Lipid Composition by iPLA2-VIA Loss Affects Synaptic
Functions. An increased proportion of shorter acyl chains in
phospholipids affects the thickness and dynamics of bio-
membrane as well as the integrity of membrane-associated pro-
teins (5). To determine the effects of altered lipid composition
by iPLA2-VIA mutations on neuronal activity, we next examined
the larval neuromuscular junctions (NMJs), which are well
characterized as neuronal synaptic models. The synaptic mor-
phology, including the number of docked vesicles, number of
boutons, number of active zones in each bouton, and bouton
size, was not changed by diPLA2-VIA loss (SI Appendix, Fig. S4
A, B, D, and E). Moreover, the overexpression of hiPLA2-VIA or
hC19orf12 or LA treatment had little effect on synaptic mor-
phology (SI Appendix, Fig. S4 A and B). However, SV diameter
in diPLA2-VIA−/− larvae was smaller than in diPLA2-VIA+/+
larvae (Fig. 4 A and B). Consistent with the reduction in SV
diameter in diPLA2-VIA−/− larvae, SV density near the active
zones of diPLA2-VIA−/− flies was higher (SI Appendix, Fig. S4C).
The SV phenotype was rescued by hiPLA2-VIAWT or dC19orf12,
but not hiPLA2-VIAA80T, and the SV density near the active
zones tended to change accordingly (SI Appendix, Fig. S4C).
Manipulation of acyl-chain composition by LA treatment also
increased SV size (Fig. 4 A and B). Spontaneous neuronal activity,
assessed by miniature excitatory junction potential (mEJP), was
decreased in diPLA2-VIA−/− flies under 2 different ambient
temperature conditions (22 and 30 °C), which was likely derived
from the small SV phenotype because SV size as well as the
number of boutons and active zones can affect mEJP amplitude
(37). LA treatment and neuronal expression of hiPLA2-VIAWT,
but not hiPLA2-VIAA80T, ameliorated the reduction in mEJP
(Fig. 4 C and D and SI Appendix, Fig. S4F). hC19orf12WT, but not
MPAN-linked hC19orf12G69R, also rescued the hypoactive mEJP
phenotype of diPLA2-VIA−/− flies. Both mEJPs and EJPs tended
to be lower in amplitude under a high temperature (30 °C) than
a favorable temperature (22 °C; Fig. 4 D and E), and EJP am-
plitude as well as quantal content did not correlate with the
alteration of lipid composition by gene manipulation and die-
tary treatment (Fig. 4E and SI Appendix, Fig. S4G). On the
contrary, the paired-pulse ratios (PPRs) of diPLA2-VIA−/− flies and
diPLA2-VIA−/− flies expressing hiPLA2-VIAA80T were decreased
by high temperature, perhaps due to the alteration in membrane
fluidity (Fig. 4E).
Alteration of Lipid Composition by iPLA2-VIA Loss Accelerates α-Syn
Fibril Formation. α-Synucleinopathy is a prominent feature of PD
patients with iPLA2-VIA mutations and NBIA patients with
C19orf12 mutations (7, 28, 38). α-Syn repeatedly binds to and
dissociates from the acidic phospholipid surface of SVs during
the release and retrieval cycle of SVs (39). To explore the effects
of altered lipid composition caused by iPLA2-VIA mutations on
α-Syn stability, we neuronally expressed α-Syn in diPLA2-VIA+/+
and diPLA2-VIA−/− flies. Aggregation of α-Syn, some of which
was ubiquitin-positive, was observed to be intensive in diPLA2-VIA−/−
DA neurons as well as other brain regions in 20-d-old adult flies,
while few α-Syn-positive aggregations were detected in age-
matched iPLA2-VIA+/+ flies (Fig. 5 A and B and SI Appendix,
Fig. S5A). Although ultrastructural analysis of adult brain tissues
revealed that loss of iPLA2-VIA itself induced the appearance of
abnormal organelle-derived membrane structures and electron-
dense deposits, α-Syn–positive electron-dense deposits were
frequently observed in the diPLA2-VIA−/− brain (SI Appendix,
Fig. S5 B and C). Biochemical analysis indicated that most of
these aggregates were sarkosyl-insoluble, suggesting that α-Syn
was transformed from a native form to a pathogenic form (Fig.
5C) (40). Importantly, dietary LA treatment suppressed the ag-
gregation and insolubilization of α-Syn (Fig. 5 A–C). Similar to
LA treatment, the neuronal expression of hiPLA2-VIAWT or
dC19orf12 ameliorated α-Syn aggregation, while hiPLA2-VIAA80T
failed to do so (Fig. 5 D and E).
To determine whether α-Syn aggregation generated in the
diPLA2-VIA−/− brain exerts seeding activity on α-Syn fibril for-
mation, we monitored the conversion of soluble α-Syn into am-
yloid fibrils by real-time quaking-induced conversion (RT-QUIC)
using fly brain lysates expressing α-Syn (41, 42). The time required
for thioflavin T (ThT) fluorescence to reach half of the fluores-
cence intensity was shorter under diPLA2-VIA loss, which was
rescued by dietary LA treatment (Fig. 5 F, Left, and SI Appendix,
Fig. S6A). In contrast, fly brain lysates without α-Syn expression
did not have the seeding activity (SI Appendix, Fig. S6B). The
slope values were not significantly different between genotypes
and were comparable to those obtained from human brain tissues
with LB pathology (SI Appendix, Fig. S6C), suggesting that fly
α-Syn aggregates have properties similar to those from human
brain (Fig. 5 F, Right). These observations strongly suggest that
lipid alteration by diPLA2-VIA loss facilitates the pathogenic
conformational change of α-Syn in fly brain.
Acyl-Chain Shortening Reduces the Affinity of α-Syn to Phospholipids.
We next examined the effects of increased shorter acyl-chain



















































phospholipids on the affinity of α-Syn to membrane. We prepared
small unilamellar vesicles (SUVs) that contained 30% 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine (DOPS) and 70% PC with different
acyl chains. A fluorescent probe to assess lipid packing, di-4-
ANEPPDHQ, indicated that SUVs containing PC 16:0_14:0
showed loosened lipid packing compared to that of SUVs con-
taining PC with C18 acyl chains (Fig. 6 A and B) (43, 44). SUVs
containing PC 16:0_14:0 had a smaller diameter than those
containing PC with C18 due to the higher curvature (Fig. 6C).
Previous studies using liposomes have shown that the N-terminal
amphiphilic helix of α-Syn recognizes packing defects and acidic
head groups of phospholipids through its hydrophobic side and
basic charged regions, respectively (45–47). Because α-Syn pre-
sents at presynapses at ∼20 μM, we incubated the above SUVs
(500 μM) with 5 μM recombinant α-Syn (48). Surprisingly, native
PAGE indicated that α-Syn lost its affinity to SUVs containing PC
16:0_14:0, while it bound by its N-terminal region to SUVs con-
taining PC with C18 acyl chains (Fig. 6D and SI Appendix, Fig.
S6D). Lack of interaction between the PC 16:0_14:0 SUVs and
α-Syn was also supported by liposome surface ζ-potential analysis,
in which α-Syn affected the ζ potential of PC 16:0_14:0 SUVs to a
lesser degree (Fig. 6E).
Discussion
In this study, using Drosophila iPLA2-VIA mutant models, we
make 3 contributions to the understanding of the etiology of PD
and NBIA. First, lack of iPLA2-VIA activity results in the
shortening of phospholipid acyl chains, which evokes ER stress
and affects neuronal activity. Second, the ectopic expression of
MPAN-associated C19orf12 rescues the neuronal phenotypes
caused by iPLA2-VIA loss. Third, α-Syn aggregation is facilitated
by phospholipids with shorter acyl chains (Fig. 7).
The structural diversity of lipids influences their geometry,
curvature, fluidity, thickness, surface charge, and lipid packing.
iPLA2-VIA, which converts phospholipids into inverse cone-
shaped lysophospholipids on the plasma membrane, releasing
FAs in the process, plays a crucial role in regulating the synaptic
transmission and electrical properties in the neuronal and glial
cells (49, 50). PLA2 activity contributes to SV formation at
synaptic terminals, as demonstrated by previous findings that
venom containing PLA2 neurotoxins promotes SV exocytosis and in-
hibits synaptic endocytosis (51, 52). Our study revealed that the phos-
pholipid acyl chains get progressively shorter in the diPLA2-VIA−/−
flies (SI Appendix, Fig. S2E). An increased proportion of shorter
acyl chains caused by iPLA2-VIA loss leads to higher membrane
curvature. Consistent with this finding, we observed reduced SV size
and mEJPs in diPLA2-VIA−/−, and diPLA2-VIA−/−;hiPLA2-VIAA80T
larval NMJs (Fig. 4 A–D), whereas EJPs of diPLA2-VIA−/− and
diPLA2-VIA−/−;hiPLA2-VIAA80T larvae were largely intact despite
the obvious seizure-paralysis phenotype at an early adult stage.
The seizure-paralysis phenotype has been reported in flies har-
boring mutations in mitochondrial proteins or ion channels and
genes associated with lipid metabolism, which might be due to
the defects in energy supply and altered channel activities on
the biomembrane (15). Thus, age-dependent alterations in the
synaptic membrane properties and mitochondrial dysfunction
might synergistically contribute to the seizure-paralysis phenotype
and early motor defects, although our diPLA2-VIA−/− flies did not
Fig. 4. Altered acyl-chain composition affects synaptic vesicle size. (A) Ultrastructure of the synaptic vesicles at the active zones in third-instar larval motor
neurons with the indicated genotypes. (Scale bar, 100 nm.) (B) The ratio of synaptic vesicle diameter to diPLA2-VI+/+ is graphed (mean ± SEM, n = 130 to
150 from 3 third-instar larvae; ***P < 0.0001 by 1-way ANOVA with the Tukey–Kramer test [Left] and by 2-tailed Student’s t test [Right]). (C) Representative
spontaneous mEJP traces in the third-instar larval NMJ at 22 and 30 °C. (D) Cumulative distribution of mEJP amplitude at 22 and 30 °C over 60 s (n = 7 to
11 third-instar larvae per genotype). (E) EJP amplitude evoked by 1.5 to 2 V electrical stimulation at 22 and 30 °C and paired-pulse ratio (PPR) as a ratio of EJP
amplitudes to paired electrical stimulations (50-ms interval) at 22 and 30 °C (n = 7 to 9 third-instar larvae per genotype; *P < 0.05 by 2-tailed Student’s t test).









































exhibit obvious mitochondrial defects. Morphological defects in
the ER and XBP1 activation at the developmental stages were
observed at least in the salivary grands, and sporadic XBP1
activation was also detected in the aged brain of diPLA2-
VIA−/− flies, suggesting that the disruption of membrane lipid
equilibrium due to iPLA2-VIA loss leads to chronic ER stress,
resulting in widespread neurodegeneration including DA neu-
ron death. Chronic ER stress would also compromise the se-
cretion of neuropeptides such as PDF, a vasoactive intestinal
peptide-like neuropeptide in flies via the ER (36). While sleep
disturbance is one of the prodromal symptoms associated with
PD (1), age-dependent defects in circadian and sleep pattern
of diPLA2-VIA−/− flies could be explained by the dysregulated
release of dopamine and PDF as well as by the disconnection
of neural circuits (SI Appendix, Fig. S1D) (19, 36).
Functions of iPAL2-VIA related to lipid metabolism have
been proposed in many in vivo studies. These functions include
membrane remodeling (14, 25), DHA and ARA metabolism (25,
53, 54), and lysophospholipid production and the subsequent
activation of store-operated Ca2+ entry (55). Our unexpected
result of acyl-chain shortening raises the possibility that iPLA2-
VIA preferentially hydrolyzes 14:0 phospholipids, which could
eventually affect the metabolism of other classes of lipids and
maintain the membrane lipid composition and ER homeostasis
(33, 56). A recent study has reported that diPLA2-VIA loss does
not alter phospholipid headgroup composition, which is consis-
tent with our findings (SI Appendix, Fig. S2D), but instead pro-
motes sphingolipid accumulation due to compromised retromer
functions, leading to further dysfunction of the retromer complex
and concomitant lysosomal stress (30). Although the phospho-
lipid acyl-chain composition was not analyzed in that study,
most of the sphingolipid molecular species that were altered in
the diPLA2-VIA–deficient flies had a 14:0 acyl chain (30). In
mammals, 16:0-lysoPC is preferentially produced by iPLA2-
VIA in activated macrophages; however, there is a lack of in-
formation on 14:0-lysoPC (57). These observations may suggest
that iPLA2-VIA recognizes 14:0 or 16:0 phospholipids at the
sn-1 position.
Lipid oxidation is exacerbated in diPLA2-VIA−/− flies, which
reveals the role of iPLA2-VIA in removing oxidized acyl chains
(14). Although our finding does not exclude the antioxidative
role of iPLA2-VIA in the biomembrane, the null effects of
α-tocopherol on motor behavior, seizure phenotype, and DA
neuron loss indicate that lipid oxidation is not a direct cause of
PLAN-linked neurodegeneration. In iPLA2-VIA–knockout mice,
there are inconsistent results regarding changes in brain lipids,
which may be due to differences in experimental methods and
the lipid and FA species investigated (25, 54). Currently, it ap-
pears to be difficult to evaluate whether our findings regarding
lipid changes in Drosophila melanogaster, which has few longer
acyl-chain lipids such as DHA- and ARA-containing phospho-
lipids, reflect the events observed in mouse models (58). Further
studies will be required to determine the molecular mechanism
of acyl-chain shortening and retromer regulation by iPLA2-VIA,
especially in mammalian models.
The regulation of MAM by C19orf12 and the up-regulation of
C19orf12 during adipocyte differentiation imply C19orf12 in-
volvement in lipid metabolism (35, 59). The rescue of iPLA2-VIA
neuronal phenotypes by C19orf12 expression provides molecular
insight into the common underlying pathogenesis of PLAN and
MPAN. Loss of iPLA2-VIA prominently alters ER morphology
in salivary gland cells, and this change may also affect the in-
tegrity of the MAM structure, through which PS transported
from the ER is converted to PE by mitochondrial PS decar-
boxylase (60). Although our phospholipid measurement method
did not detect PS with high sensitivity, the abundance of PE was
not changed by iPLA2-VIA loss, suggesting that PE synthesis is
largely dependent on, or is compensatorily bypassed through, the
Fig. 5. Alteration of phospholipid composition by diPLA2-VIA loss promotes
α-Syn aggregation. (A–C) α-Syn accumulation by diPLA2-VIA loss is relieved
by the LA diet. (A) Brain tissues from 15-d-old flies were stained with the
indicated antibodies. An arrowhead indicates ubiquitin- and α-Syn–positive
punctum. (Scale bar, 2 μm.) (B) Ubiquitin- and α-Syn–positive puncta in TH-
positive neurons are graphed (n = 10 to 15 neurons from 6 flies at 15 d old
per sample; *P < 0.05 and **P < 0.01 by 1-way ANOVA with the Tukey–
Kramer test). (C) Sarkosyl-soluble and -insoluble fractions from brain tissues
from 20-d-old flies were analyzed by Western blot. The band intensities of
α-Syn normalized to those of actin are graphed (n = 4; *P < 0.05 and **P <
0.01 by Dunnett’s test). (D and E) α-Syn accumulation caused by diPLA2-VIA
loss is suppressed by hiPLA2-VIA or dC19orf12. (D) Brain tissues from 15-d-old
flies were stained with the indicated antibodies. An arrowhead indicates
ubiquitin- and α-Syn–positive punctum. (Scale bar, 2 μm.) (E) Ubiquitin- and
α-Syn–positive puncta in TH-positive neurons are graphed (n = 10 to
15 neurons from 6 flies at 15 d old per sample; *P < 0.05 by 1-way ANOVA
with the Tukey–Kramer test). (F) diPLA2-VIA loss promotes the seeding ac-
tivity of α-Syn. Brain lysates prepared from 15-d-old flies neuronally
expressing α-Syn were subjected to RT-QUIC. Graphs indicate the time when
TdT fluorescence reached an intensity of 165,000 RFU (Left, t1/2) and the
slope obtained by differential processing of plot curves (Right), respectively.
When TdT fluorescence did not reach 165,000 RFU before 120 h, the value of
t1/2 was defined as 120 (n = 3 replicates from 3 flies per sample; *P < 0.05 by
1-way ANOVA with the Tukey–Kramer test). N.S., not significant; RFU, rel-
ative fluorescence units.



















































Kennedy pathway. Nevertheless, the rescue of ER stress in
diPLA2-VIA−/− flies by C19orf12 raises the possibility that the
enhancement of MAM integrity alleviates membrane lipid
disequilibrium.
Similar to postmortem studies in INAD and PARK14,
diPLA2-VIA−/− flies exhibited ubiquitinated α-Syn accumulation
in DA neurons as well as other types of neurons (Fig. 5 and SI
Appendix, Fig. S5), a phenomenon that was rescued by C19orf12;
C19orf12 mutations also lead to α-Syn accumulation and sub-
sequent LB formation (28). The interaction between α-Syn and
lipids modulates α-Syn fibril formation in different ways, and
there have been controversial observations of the pathological
roles of the lipid membrane in terms of α-Syn aggregation (2, 61–
63). Our fly models suggest that changes in the acyl-chain com-
position of phospholipids are more critical for α-Syn aggregation
than changes in the head group. Although we cannot exclude the
possibility that decreased unsaturation of acyl chains contributed
to neurodegeneration in our Drosophila models, the results of
the liposome assay indicate that the status of lipid packing pro-
duced by the geometry of acyl chains in the lipid bilayers affects
α-Syn stability. Increased shorter acyl chains would lead to higher
membrane curvature and larger packing defects, whereas the
polyunsaturation of acyl chains shallows the hydrophobic groove
(64). While lipid-packing defects facilitate α-Syn insertion into
the membrane (46, 65), α-Syn loses its affinity to SUVs con-
taining PC with shorter acyl chains (Fig. 6). This inconsistency
may derive from differences in the depth of the hydrophobic
groove and the state of the gel/liquid crystalline phases gener-
ated by different FA compositions (49, 66). Nevertheless, the
finding that α-Syn lacking 30 N-terminal residues (ΔN30) has
greater in vivo seeding activity than full-length α-Syn supports
our idea (67). The N-terminal helical segment of α-Syn, com-
posed of 25 residues, has been demonstrated to function as a
membrane anchor, and ΔN30 failed to bind to liposomes in our
assay (SI Appendix, Fig. S6D) (68). Considering the previous
related studies, our data suggest that nonmembrane-bound
α-Syn carries a risk of aggregation and/or that the association
of α-Syn with membranes that contain shorter acyl chains con-
tributes to its aggregation (69).
The observation that the correction of phospholipid compo-
sition by dietary LA treatment alleviates the ER stress and the
neuronal phenotypes of diPLA2-VIA−/− flies strongly suggests
that acyl-chain shortening of phospholipids in the brain could be
the major pathogenic mechanism underlying PLAN-linked neu-
rodegeneration (SI Appendix, Fig. S7). The administration of a
diet containing lower amounts of polyunsaturated phospholipids
causes a decrease in the speed and sensitivity of phototransduction
in Drosophila (24). In the mammalian brain, PUFAs including LA
are supplied through the blood, indicating that altered dietary
intake of PUFAs could affect neuronal functions (70). The re-
lationship between dietary intake of FAs and PD has been in-
vestigated. Cohort studies showed that dietary intake of vitamin E
had little effect on PD risk (71), while intake of unsaturated FAs
reduced PD risk (72). In contrast, saturated fat and ω-6 PUFAs
might be associated with PD risk (73, 74). Although beneficial FAs
in humans corresponding to LA in Drosophila need to be de-
termined, our study indicates that the dietary manipulation of
FAs is a promising method to control risks for PD and related
disorders.
Fig. 7. Working hypothesis. Loss of iPLA2-VIA causes the shortening of
phospholipid acyl chains in the brain, which alters membrane fluidity, lipid
packing, and curvature. α-Syn affinity to the synaptic membrane is weak-
ened by altered phospholipid properties, leading to α-Syn aggregation.
These altered membrane properties also induce ER stress, affect the dy-
namics of SVs, and provoke abnormal neurotransmission, which manifests as
the bang-sensitivity phenotype. Correction of the membrane composition by
dietary intake of FAs or enhanced MAM integrity by C19orf12 rescues
neurodegeneration and α-Syn aggregation.
Fig. 6. A shorter acyl-chain composition weakens α-Syn association with
liposomes. (A and B) Lipid packing status of SUVs. (A) SUVs containing 30%
DOPS and 70% of the indicated phospholipids were incubated with 250 nM
di-4-ANEPPDHQ, and the fluorescence intensities at 630 and 530 nm were
imaged (Upper). The 630-nm signal divided by the thresholded 530-nm sig-
nal intensity is also shown (Lower). (Scale bar, 2 μm.) (B) The 630/530-nm
intensity ratios are graphed (n = 3 to 4; *P < 0.05, **P < 0.01, and ***P <
0.005 by 1-way ANOVA with the Tukey–Kramer test). (C) Diameter (in
nanometers) of SUVs containing 30% DOPS and 70% of the indicated
phospholipids (mean ± SEM; 3 trials). (D) α-Syn does not bind to SUVs con-
taining shorter acyl chains. Five micromolar recombinant α-Syn incubated
with 500 μM SUV as prepared in A–C for 10 min was separated by clear-
native PAGE (CN-PAGE) or SDS/PAGE. Dots and open bracket indicate a
monomer form of α-Syn and slower-migrating forms of α-Syn due to the
interaction with SUV, respectively. Graph represents the ratios of α-Syn
monomer signals to a control without SUV on CN-PAGE, normalized to
α-Syn signals that appeared on SDS/PAGE as inputs (n = 3; **P < 0.01 and
***P < 0.001 by Dunnett’s test). (E) ζ Potentials of SUVs with recombinant
α-Syn are indicated as a ratio to that of control liposomes without proteins.










































Extended experimental procedures are described in SI Appendix, SI Materials
and Methods. All vectors, Drosophila stocks, and primary antibodies are
listed in SI Appendix, Tables S1–S3.
Fly Stocks. Fly culture and crosseswereperformedon standard fly food containing
yeast, cornmeal, and molasses, and the flies were raised at 25 °C. Comple-
mentary DNAs (cDNAs) for hiPLA2-VIA, hc19orf12, and their disease-associated
mutants were subcloned into the pUAST attB vector using the In-fusion HD




TAACGAATTCTAGTCATCATACTGGATCT-3′ for hc19orf12. The transgenic lines
were generated on y1w1118;pBac{y+-attP-3B}VK00037 (Bloomington stock
9752) background (BestGene). pUAS-ER-mAG1 was subcloned from pER-mAG1
(MBL, AM-V0202M), and transgenic lines were generated on the w1118
background (BestGene). All other fly stocks and GAL4 lines used in this
study were obtained from the Bloomington Drosophila Stock Center and
Kyoto Stock Center. UAS-α-SynucleinLP2 (75) and UAS-mito-TdTomato (76)
were gifts from L. J. Pallanck, University of Washington School of Medi-
cine, and T. Uemura, Kyoto University Graduate School of Biostudies, re-
spectively. Stocks were backcrossed to the w1118 wild-type background
for 6 generations.
Generation of diPLA2-VIA Null Allele. The diPLA2-VIA null allele was gener-
ated by CRISPR-Cas9 technology using tandem guide RNA plasmids (pCFD4)
and a fly line expressing Cas9 during oogenesis (Bloomington stock 54591).
Two protospacers corresponding to sequences of dIPLA2-VIA were cloned




To avoid potential off-target mutations generated by Cas9, the diPLA2-VIA
null allele was backcrossed to the w1118 background for 6 generations, and
w1118 was used as a control allele. The sequences of the forward and reverse
primers for genotyping were as follows:
iPLA2-VIA genomic Fw, 5′-CGGTGACATCGCTAATAAAGCTGC; iPLA2-VIA
genomic Rev, 5′-GCGGTCTAAATCCGTCTTGCATG.
Quantitative Reverse Transcription-PCR. Full details of quantitative reverse
transcription PCR are provided in SI Appendix, SI Materials and Methods.
Imaging and EM Analysis. Full details of imaging and EM analysis are provided
in SI Appendix, SI Materials and Methods.
Administration of FAs and α-Tocopherol. Flies were reared on either a plain
diet (Formula 4–24 Plain Drosophila Medium; Carolina Biological Supply); a
diet with the addition of one of the following FAs at 5 μL/mL unless oth-
erwise indicated: linoleic acid (L1012; Sigma-Aldrich), stearic acid (198-12481;
Wako), or myristic acid (134-03435; Wako); or a diet with 25 IU/mL
α-tocopherol (207-01792; Wako) as reported previously (24, 77, 78).
Lipid Extraction and Lipids Analysis by Electrospray Ionization Mass
Spectrometry (ESI-MS). Samples for ESI-MS of lipids were prepared and an-
alyzed as described previously (79). In brief, brain tissues of flies reared on a
plain diet (Formula 4–24 Plain Drosophila Medium) or a diet with the ad-
dition of 5 μL/mL LA were soaked in 200 μL of 50 mM Tris·HCl (pH 7.4) and
then homogenized on ice for 1 min. Lipids were extracted from the ho-
mogenates by the Bligh and Dyer method (79). Analysis was performed us-
ing a quadrupole-linear ion-trap hybrid mass spectrometer (4000Q-TRAP;
Sciex) equipped with a liquid chromatograph (Nexera X2 system; Shimadzu).
As an internal standard, 500 pmol of d5-labeled eicosapentaenoic acid was
added to each sample. Samples injected by an autosampler were separated
using a step gradient with mobile phase A (acetonitrile/methanol/water =
1:1:1 [vol/vol/v] containing 5 μM phosphoric acid and 1 mM ammonium
formate) and mobile phase B (2-propanol containing 5 μM phosphoric acid
and 1 mM ammonium formate) at a flow rate of 0.2 mL/min at 50 °C.
Identification was conducted using multiple reaction monitoring transition
and retention times, and quantification was performed based on the peak
area of the multiple reaction monitoring transition and calibration curve
obtained with an authentic standard for each compound, as described
previously (79).
Biochemical Analysis and α-Syn Fractionation. Full details of biochemical
analysis and α-Syn fractionation are provided in SI Appendix, SI Materials
and Methods.
RT-QUIC. Recombinant human α-Syn protein was purified from Escherichia
coli BL21 harboring pRK172-α-Syn (Y136-TAT) as previously reported (80). A
female fly head homogenized in 20 μL of ice-cold phosphate buffered
saline (PBS) supplemented with 1/100 protease inhibitor mixture (Nacalai)
in 1.5-mL tubes was sonicated for 3 min on ice using a sonicator (Branson
Sonifier 250, micro tip power 3 to 4, 30 s sonication/30 s pause, 3 times).
After centrifugation at 2,000 × g for 2 min at 4 °C to remove debris, the
supernatant diluted with PBS at 1:10 was used as a fly brain sample. The RT-
QUIC assay was performed according to a reported protocol (41). Briefly, the
RT-QUIC reaction buffer (RB) was composed of 100 mM phosphate buffer
(pH 8.2), 10 μM ThT, and 0.1 mg/mL recombinant α-Syn. Each well of a black
96-well plate with a clear bottom (Nalgene Nunc) contained 95 μL of RB and
37 ± 3 mg of 0.5-mm zirconium/silica beads (Thistle Scientific). Reactions
were seeded with 5 μL of fly brain samples to a final reaction volume of 100
μL. The plates were sealed with plate sealer film (Greiner Bio-One) and in-
cubated in a FLUOstar OPTIMA microplate reader (BMG Labtech) at 30 °C for
120 h with intermittent shaking cycles: double-orbital with 1 min of shaking
at 200 rpm followed by 14 min of rest. ThT fluorescence measurements
(450 nm excitation and 480 nm emission) were taken every 15 min.
Liposome Assay. DLPC, DOPC, DSPC, PC16:0_14:0, and DOPS were purchased
fromAvanti Polar Lipids. DLPC/DOPS (7:3), DOPC/DOPS (7:3), DSPC/DOPS (7:3),
and PC16:0_14:0/DOPS (7:3) in chloroform were dried by a nitrogen evapo-
rator. The lipids resuspended in 1 mL of 50 mM NaCl were prepared by se-
quential extrusion through 0.1-μm and 0.05-μm filters by using a hand
extruder (Avanti Polar Lipids). The suspension of 50 μM liposomes with or
without recombinant 5 μM α-Syn vortexed briefly was incubated for 10 min
at RT, and liposome size and ζ potentials were measured using a Zetasizer-
NanoZSP (Malvern Instruments). For CN-PAGE, 5 μM α-Syn with or without
500 μM liposomes in TBS (pH 7.4) vortexed briefly was incubated for
10 min at RT. The samples were mixed with 4× CN-PAGE sample buffer and
separated on a 4 to 16% Bis-Tris gel (Thermo Fisher Scientific). NativeMark
Unstained Protein Standard (Thermo Fisher Scientific) was used to esti-
mate molecular mass. The gel was run at 100 V for 100 min and was
stained with One-step Coomassie brilliant blue staining reagent (Bio
Craft). To assess packing defects, 100 μM liposomes incubated with 250 nM
di-4-ANEPPDHQ dye at RT for 30 min were analyzed using confocal mi-
croscopy (LSM880; Zeiss).
Drosophila Behavior Assays and Survival Assay. Full details of Drosophila
behavior assays and survival assay are provided in SI Appendix, SI Materials
and Methods.
Electrophysiology. Third-instar larvae were dissected in HL-3, and mEJPs from
NMJs were recorded using an electrophysiological setup equipped with an
Eclipse FN1 microscope (Nikon), a Multiclamp 700B amplifier (Molecular
Devices), and a Digidata 1550A data acquisition system (Molecular Devices).
Dissected larvae were incubated in HL-3 containing 2.5 mM (for EJP) or
0.375 mM (for mEJP) Ca2+, and a recording electrode filled with 3 M KCl was
inserted into muscle 6 of the A3 segment containing NMJs. All data were
analyzed using Mini-Analysis software (Synaptosoft). Quantal content was
calculated as the mean EJP amplitude divided by the mean mEJP amplitude,
as previously described (37).
Statistical Analyses. Error bars in graphs represent the mean ± SEM. The exact
sample size (e.g., the number of flies, brains, or neurons) of each experiment
is provided in the relevant figures. A 2-tailed Student’s t test or 1-way
repeated-measures ANOVA was used to detect significant differences be-
tween 2 or among multiple groups, respectively, unless otherwise indicated.
If a significant result was detected using ANOVA (P < 0.05), the mean values
of the control and the specific test group were analyzed using the Tukey–
Kramer test. Dunnett’s test was used to detect significant differences be-
tween 2 specific groups or among multiple groups of interest. Data distri-
bution was assumed to be normal, but this was not formally tested. Data
collection and analysis were performed by researchers (A.M., T.I., K.S.-F.,
H.M., S.S., and A.O.) blinded to the conditions in key experiments (Figs. 1E,
2D, 3 D and F, 5 B, E, and F and SI Appendix, Figs. S1G, S2 E, F, and J, S3J, and
S6 A and B).
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